Načítá se...
FGF19 and FGF21: In NASH we trust
OBJECTIVE: FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development. METHODS: We performed a detailed analyses of published preclinical and clinical data to o...
Uloženo v:
| Vydáno v: | Mol Metab |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8085573/ https://ncbi.nlm.nih.gov/pubmed/33383173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2020.101152 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|